Jon Hamilton | KGOU
KGOU

Jon Hamilton

Jon Hamilton is a correspondent for NPR's Science Desk. Currently he focuses on neuroscience and health risks.

In 2014, Hamilton went to Liberia as part of the NPR team that covered Ebola. The team received a Peabody Award for its coverage.

Following the 2011 earthquake and tsunami in Japan, Hamilton was part of NPR's team of science reporters and editors who went to Japan to cover the crisis at the Fukushima Dai-ichi nuclear power plant.

Hamilton contributed several pieces to the Science Desk series "The Human Edge," which looked at what makes people the most versatile and powerful species on Earth. His reporting explained how humans use stories, how the highly evolved human brain is made from primitive parts, and what autism reveals about humans' social brains.

In 2009, Hamilton received the Michael E. DeBakey Journalism Award for his piece on the neuroscience behind treating autism.

Before joining NPR in 1998, Hamilton was a media fellow with the Henry J. Kaiser Family Foundation studying health policy issues. He reported on states that have improved their Medicaid programs for the poor by enrolling beneficiaries in private HMOs.

From 1995-1997, Hamilton wrote on health and medical topics as a freelance writer, after having been a medical reporter for both The Commercial Appeal and Physician's Weekly.

Hamilton graduated with honors from Oberlin College in Ohio with a Bachelor of Arts in English. As a student, he was the editor of the Oberlin Review student newspaper. He earned his master's degree in journalism from Columbia University, where he graduated with honors. During his time at Columbia, Hamilton was awarded the Baker Prize for magazine writing and earned a Sherwood traveling fellowship.

Fossils offer a detailed record of early human skulls but not the brains inside them.

So researchers have been using genetic material taken from those fossils to search for clues about how the human brain has evolved over hundreds of thousands of years.

And now they have succeeded in growing human brain organoids, or "minibrains," that contain the Neanderthal variant of a gene called NOVA1, a team reports in the journal Science.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

AUDIE CORNISH, HOST:

There's new evidence that brain stimulation isn't a one-size-fits-all treatment.

Customizing treatment for each person led to better results with both depression and obsessive-compulsive behaviors, researchers report in the journal Nature Medicine.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Early in the pandemic, people with COVID-19 began reporting an odd symptom: the loss of smell and taste.

The reason wasn't congestion. Somehow, the SARS-CoV-2 virus appeared to be affecting nerves that carry information from the nose to the brain.

That worried neurologists.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

Scientists are learning that COVID-19 can cause long-term damage to the brain. Problems with memory and thinking may linger for months after an infection. NPR's Jon Hamilton reports that COVID-19 may even increase the risk of Alzheimer's.

A chemically tweaked version of the psychedelic drug ibogaine appears to relieve depression and addiction symptoms without producing hallucinations or other dangerous side effects.

The results of a study in rodents suggest it may be possible to make psychedelic drugs safe enough to become mainstream treatments for psychiatric disorders, the authors report Wednesday in the journal Nature.

The actual number of coronavirus infections in the U.S. reached nearly 53 million at the end of September and could be approaching 100 million now, according to a model developed by government researchers.

The model, created by scientists at the Centers for Disease Control and Prevention, calculated that the true number of infections is about eight times the reported number, which includes only the cases confirmed by a laboratory test.

The Food and Drug Administration has approved a drug that extends the lives of children with an extremely rare genetic disorder that causes them to grow old before they grow up.

The disorder, progeria, ages cells rapidly and prematurely. As a result, affected children remain small and begin to look frail and old by the time they reach school age. Most die of heart disease in their early teens.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

LULU GARCIA-NAVARRO, HOST:

During deep sleep, the brain appears to wash away waste products that increase the risk for Alzheimer's disease.

A host of new research studies suggest that this stage of sleep — when dreams are rare and the brain follows a slow, steady beat – can help reduce levels of beta-amyloid and tau, two hallmarks of the disease.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

We continue to learn about the connection between sleep and Alzheimer's disease. NPR's Jon Hamilton brings us this report done with the NPR science podcast Short Wave.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

In other news, hopes for an experimental drug for Alzheimer's disease took a big hit today. It failed to win support from a panel of experts who advise the Food and Drug Administration. NPR science correspondent Jon Hamilton is on the line.

The substance that makes some mushrooms "magic" also appears to help people with major depressive disorder.

A study of 27 people found that a treatment featuring the hallucinogen psilocybin worked better than the usual antidepressant medications, a team reported Wednesday in the journal JAMA Psychiatry.

If you fall off a bike, you'll probably end up with a cinematic memory of the experience: the wind in your hair, the pebble on the road, then the pain.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AUDIE CORNISH, HOST:

Medical research was an early casualty of the COVID-19 pandemic.

After cases began emerging worldwide, thousands of clinical trials unrelated to COVID-19 were paused or canceled amid fears that participants would be infected. But now some researchers are finding ways to carry on in spite of the coronavirus.

Researchers appear to have shown how the brain creates two different kinds of thirst.

The process involves two types of brain cells, one that responds to a decline in fluid in our bodies, while the other monitors levels of salt and other minerals, a team reports in the journal Nature.

Together, these specialized thirst cells seem to determine whether animals and people crave pure water or something like a sports drink, which contains salt and other minerals.

Mental illness can run in families. And Dr. Kafui Dzirasa grew up in one of these families.

His close relatives include people with schizophrenia, bipolar disorder and depression. As a medical student, he learned about the ones who'd been committed to psychiatric hospitals or who "went missing" and were discovered in alleyways.

Dzirasa decided to dedicate his career to "figuring out how to make science relevant to ultimately help my own family."

Out-of-body experiences are all about rhythm, a team reported Wednesday in the journal Nature.

In mice and one person, scientists were able to reproduce the altered state often associated with ketamine by inducing certain brain cells to fire together in a slow, rhythmic fashion.

Pages